GTHP: AI 评分 44/100 — AI 分析 (4月 2026)

Key Facts: AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Guided Therapeutics, Inc. is a medical device company specializing in non-invasive cervical cancer detection with its LuViva device. Targeting point-of-care diagnostics, the company operates in a competitive medical device market, facing challenges in commercialization and market adoption within the broader healthcare sector.

GTHP是做什么的？

Guided Therapeutics, Inc., originally incorporated as SpectRx, Inc. in 1992, rebranded in 2008 to focus on medical device development. The company's core product is LuViva, a non-invasive device designed for the detection of cervical cancers and precancers. LuViva employs optical scanning technology to analyze reflected and fluorescent light from the cervix, providing a point-of-care diagnostic tool. The company aims to offer a painless and non-invasive alternative to traditional methods like Pap smears and biopsies. Guided Therapeutics operates primarily in the United States, seeking to expand its market reach through strategic partnerships and regulatory approvals in other regions. The company's business model centers on the commercialization and distribution of LuViva to healthcare providers, including gynecologists and clinics. Guided Therapeutics faces competition from established diagnostic companies and alternative screening methods. The company is based in Norcross, Georgia, and is led by CEO Mark L. Faupel, who manages a small team of four employees.

GTHP的投资论点是什么？

Guided Therapeutics, Inc. presents a high-risk, high-reward investment profile. The company's LuViva device targets a critical need for improved cervical cancer screening, offering a potential alternative to traditional methods. However, the company's financial performance, with a negative profit margin of -1478.7% and reliance on OTC markets, raises concerns about its long-term viability. The success of Guided Therapeutics hinges on successful commercialization of LuViva, regulatory approvals, and market adoption. Investors should carefully consider the company's limited resources, competitive landscape, and dependence on future funding to sustain operations. The company's beta of 0.56 suggests lower volatility compared to the broader market.

GTHP在哪个行业运营？

Guided Therapeutics operates within the medical device industry, specifically targeting the cervical cancer screening market. This market is characterized by established screening methods like Pap smears and HPV tests, as well as emerging technologies. The competitive landscape includes companies offering alternative diagnostic solutions and established players in women's health. The global cervical cancer screening market is expected to grow, driven by increasing awareness and the need for more effective and accessible screening methods. Guided Therapeutics aims to capture a share of this market with its LuViva device, offering a point-of-care, non-invasive option.

Medical - Devices

Healthcare

GTHP有哪些增长机遇？

Market Expansion: Guided Therapeutics has the opportunity to expand its market reach beyond the United States by obtaining regulatory approvals in other countries. The global cervical cancer screening market presents a significant opportunity for growth, particularly in developing countries with limited access to traditional screening methods. Successful international expansion could significantly increase LuViva sales and revenue.
Strategic Partnerships: Collaborating with established healthcare providers and distributors can accelerate the adoption of LuViva. Partnering with large hospital networks, clinics, and women's health organizations can provide access to a wider patient base and enhance the credibility of the device. Strategic alliances can also facilitate market entry into new geographic regions.
Product Development: Enhancing the capabilities of the LuViva device through further research and development can improve its accuracy and expand its applications. Developing new features, such as integration with electronic health records or improved data analytics, can increase the value proposition of the device and attract more customers. Continuous innovation is essential to maintain a competitive edge in the medical device industry.
Direct-to-Consumer Marketing: Implementing a direct-to-consumer marketing strategy can raise awareness of LuViva and drive demand for the device. Educating women about the benefits of non-invasive cervical cancer screening can increase patient interest and encourage them to discuss LuViva with their healthcare providers. Effective marketing campaigns can also help to overcome resistance to new technologies.
Point-of-Care Diagnostics: Capitalizing on the growing trend towards point-of-care diagnostics can drive adoption of LuViva. Point-of-care testing offers convenience and faster results, which can improve patient compliance and reduce the time to diagnosis. As healthcare systems increasingly prioritize efficiency and patient-centered care, the demand for point-of-care diagnostic solutions is expected to grow.

Market capitalization of $0.02 billion indicates a micro-cap company with limited financial resources.
Negative P/E ratio of -8.69 reflects the company's current lack of profitability.
Gross margin of 33.7% suggests potential for profitability if sales volume increases and operating expenses are managed effectively.
Profit margin of -1478.7% highlights significant losses and the need for improved cost management.
The company operates with only 4 employees, indicating a lean organizational structure and reliance on external partnerships.

GTHP提供哪些产品和服务？

Develops and commercializes medical devices.
Focuses on cervical cancer detection technology.
Offers LuViva, a non-invasive cervical scan.
Provides point-of-care diagnostic solutions.
Aims to improve early detection of cervical cancers and precancers.
Utilizes optical scanning technology for cervical analysis.

GTHP如何赚钱？

Sells LuViva devices to healthcare providers.
Generates revenue from device sales and related services.
Targets gynecologists, clinics, and hospitals.
Focuses on point-of-care diagnostics market.

Gynecologists
Hospitals
Clinics
Women's health centers

Proprietary LuViva technology.
Non-invasive cervical cancer detection method.
Point-of-care diagnostic capability.
Potential for improved patient compliance.

什么因素可能推动GTHP股价上涨？

Upcoming: Potential regulatory approvals for LuViva in new geographic regions.
Upcoming: Strategic partnerships with healthcare providers and distributors.
Ongoing: Continued commercialization efforts for LuViva in the United States.
Ongoing: Research and development of new features for the LuViva device.
Ongoing: Direct-to-consumer marketing campaigns to raise awareness of LuViva.

GTHP的主要风险是什么？

Potential: Competition from established screening methods and alternative technologies.
Potential: Regulatory hurdles and delays in obtaining approvals.
Ongoing: Limited financial resources and dependence on future funding.
Ongoing: Negative profit margin and need for improved cost management.
Potential: Limited market adoption and resistance to new technologies.

GTHP的核心优势是什么？

Non-invasive cervical cancer detection.
Point-of-care diagnostic capability.
Proprietary LuViva technology.
Potential for improved patient compliance.

GTHP的劣势是什么？

Limited financial resources.
Negative profit margin.
Small number of employees.
Reliance on OTC markets.

GTHP有哪些机遇？

Market expansion into new geographic regions.
Strategic partnerships with healthcare providers.
Product development and innovation.
Direct-to-consumer marketing.

GTHP面临哪些威胁？

Competition from established screening methods.
Regulatory hurdles.
Limited market adoption.
Dependence on future funding.

GTHP的竞争对手是谁？

AccSys Technology, Inc. — Offers medical imaging and treatment solutions. — (ACMSY)
Asante Solutions, Inc. — Develops diabetes management solutions. — (ASAPF)
Biotech Cyto Inc. — Specializes in cancer diagnostics and therapeutics. — (BTCY)
Cerevo Inc. — Develops connected sports devices and solutions. — (CRVW)
Emiti Ltd. — Focuses on medical device development and manufacturing. — (EMITF)

Key Metrics

MoonshotScore: 44/100

Company Profile

CEO: Mark L. Faupel
Headquarters: Norcross, US
Employees: 4
Founded: 2021

AI Insight

AI analysis pending for GTHP

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Guided Therapeutics, Inc. do?

Guided Therapeutics, Inc. is a medical technology company focused on developing and commercializing the LuViva advanced cervical scan. LuViva is a non-invasive point-of-care device designed for the early detection of cervical cancers and precancers. The device uses optical scanning technology to analyze reflected and fluorescent light from the cervix, providing a real-time assessment. Guided Therapeutics aims to offer a more convenient and patient-friendly alternative to traditional screening methods like Pap smears and biopsies.

What do analysts say about GTHP stock?

There is currently no available analyst coverage for GTHP stock. Given its OTC listing and micro-cap status, Guided Therapeutics may not attract significant attention from major research firms. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making an investment decision. Key valuation metrics, such as revenue growth, profitability, and cash flow, should be carefully analyzed.

What are the main risks for GTHP?

Guided Therapeutics faces several significant risks. The company's limited financial resources and negative profit margin raise concerns about its ability to sustain operations and fund future growth. Competition from established screening methods and alternative technologies poses a challenge to market adoption of LuViva. Regulatory hurdles and delays in obtaining approvals can also impact the company's timeline and financial performance. Furthermore, the company's reliance on OTC markets increases the risk of illiquidity and price volatility.

What revenue streams does Guided Therapeutics, Inc. have in healthcare?

Guided Therapeutics, Inc.'s primary revenue stream is currently derived from the sales of its LuViva device to healthcare providers, including gynecologists, clinics, and hospitals. The company generates revenue from the initial sale of the device and potentially from ongoing service and maintenance contracts. As the company expands its market reach and increases adoption of LuViva, it may explore additional revenue streams, such as consumables or subscription-based services. However, the company's current revenue model is heavily reliant on device sales.

How does Guided Therapeutics, Inc. manage patent expiration risks?

Guided Therapeutics, Inc. relies on patents to protect its proprietary LuViva technology. While the provided data does not give specific details on patent expiration dates, the company must actively manage its intellectual property portfolio to mitigate the risks associated with patent expirations. This includes seeking new patents for innovations and improvements to the LuViva device, as well as developing strategies to extend the life cycle of its existing patents. The company should also monitor the competitive landscape for potential patent infringement and take appropriate legal action to protect its intellectual property rights.